Know Cancer

or
forgot password

PTEN Determination in Squamous Cell Cancer of The Head and Neck Treated on E5397, A Randomized Phase III Trial of Cisplatin Plus Placebo Versus Cisplatin Plus C225 (Cetuximab) in Metastatic/Recurrent Head and Neck Cancer


Phase 3
18 Years
N/A
Not Enrolling
Both
Head and Neck Cancer

Thank you

Trial Information

PTEN Determination in Squamous Cell Cancer of The Head and Neck Treated on E5397, A Randomized Phase III Trial of Cisplatin Plus Placebo Versus Cisplatin Plus C225 (Cetuximab) in Metastatic/Recurrent Head and Neck Cancer


OBJECTIVES:

Primary

- Compare cetuximab activity, as reflected in response rate (RR), in PTEN-deficient and
PTEN-expressing cancers.

Secondary

- Examine RR, progression-free survival (PFS), and overall survival (OS) in
PTEN-deficient and PTEN-expressing cancers, by treatment arm.

OUTLINE: Tissue microarray slides collected earlier from ECOG-E5397 are immunostained with
PTEN antibody and analyzed with AQUA.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Treated on protocol ECOG-E5397

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Cetuximab activity as reflected in RR

Safety Issue:

No

Principal Investigator

Barbara A. Burtness, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fox Chase Cancer Center

Authority:

Unspecified

Study ID:

CDR0000715505

NCT ID:

NCT01466244

Start Date:

December 2011

Completion Date:

Related Keywords:

  • Head and Neck Cancer
  • metastatic squamous neck cancer with occult primary squamous cell carcinoma
  • recurrent metastatic squamous neck cancer with occult primary
  • recurrent squamous cell carcinoma of the hypopharynx
  • recurrent squamous cell carcinoma of the larynx
  • recurrent squamous cell carcinoma of the lip and oral cavity
  • recurrent squamous cell carcinoma of the oropharynx
  • recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage III squamous cell carcinoma of the hypopharynx
  • stage III squamous cell carcinoma of the larynx
  • stage III squamous cell carcinoma of the lip and oral cavity
  • stage III squamous cell carcinoma of the oropharynx
  • stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVA squamous cell carcinoma of the larynx
  • stage IVA squamous cell carcinoma of the lip and oral cavity
  • stage IVA squamous cell carcinoma of the oropharynx
  • stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVB squamous cell carcinoma of the larynx
  • stage IVB squamous cell carcinoma of the lip and oral cavity
  • stage IVB squamous cell carcinoma of the oropharynx
  • stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IVC squamous cell carcinoma of the larynx
  • stage IVC squamous cell carcinoma of the lip and oral cavity
  • stage IVC squamous cell carcinoma of the oropharynx
  • stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
  • untreated metastatic squamous neck cancer with occult primary
  • Neoplasms, Squamous Cell
  • Head and Neck Neoplasms

Name

Location